KLRS

SEC source: 0000899243-22-013334 · doc4.xml · derivative · entry 3

Miller Edward · CIK 0001619252 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,744

Underlying: Common Stock · 56,744 shares

Expires 2032-01-18

F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-22-013334 · doc4.xml · nonDerivative · entry 1

Miller Edward · CIK 0001619252 · General Counsel

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 217,307

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-22-013339 · doc4.xml · derivative · entry 2

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 42,558

Underlying: Common Stock · 42,558 shares

Expires 2032-01-18

F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-22-013339 · doc4.xml · nonDerivative · entry 1

Hagen Brett R · CIK 0001681782 · Chief Accounting Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 80,644

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-22-013338 · doc4.xml · derivative · entry 3

Sinha Vikas · CIK 0001337845 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 119,162

Underlying: Common Stock · 119,162 shares

Expires 2032-01-18

F3 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-22-013338 · doc4.xml · nonDerivative · entry 1

Sinha Vikas · CIK 0001337845 · Director · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 907,795

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-22-013331 · doc4.xml · derivative · entry 2

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 56,744

Underlying: Common Stock · 56,744 shares

Expires 2032-01-18

F2 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-22-013331 · doc4.xml · nonDerivative · entry 1

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 405,640

F1 · shares: The shares reported in this transaction represent Restricted Stock Units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0001209191-23-006990 · doc4.xml · derivative · entry 5

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 366,344

Underlying: Common Stock · 56,744 shares

Expires 2032-01-18

F5 · derivative.exercise_date: 25% of this option shall vest and become exercisable on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0001209191-23-006990 · doc4.xml · nonDerivative · entry 1

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 51,256

F1 · shares: The shares reported in this transaction represent restricted stock units ("RSUs") issued under the AlloVir, Inc. 2020 Stock Option and Grant Plan (the "Plan"). Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. 25% of the RSUs shall vest on January 18, 2023, with the remainder vesting in twelve equal quarterly installments thereafter.

SEC source: 0000899243-21-046758 · doc4.xml · nonDerivative · entry 1

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 402,878

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.79 to $17.41. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-044889 · doc4.xml · nonDerivative · entry 4

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,288,154

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.

F3 · ownership.nature: Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-045272 · doc4.xml · nonDerivative · entry 1

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 403,392

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.52 to $21.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-044889 · doc4.xml · nonDerivative · entry 3

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,288,254

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.75 to $22.35. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-044889 · doc4.xml · nonDerivative · entry 2

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,294,376

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.99 to $23.27. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-044889 · doc4.xml · nonDerivative · entry 1

Leen Ann M. · CIK 0001763026 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 2,294,876

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 2, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $21.81 to $22.66. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

F3 · ownership.nature: Shares held by the Ann M. Leen Management Trust, for which the Reporting Person serves as trustee. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-044619 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2-TPO Investments, LLC

Disclosed balance after: 342,693

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-044619 · doc4.xml · nonDerivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2 MG Limited

Disclosed balance after: 1,375,262

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.78, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-043670 · doc4.xml · nonDerivative · entry 4

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2-TPO Investments, LLC

Disclosed balance after: 342,813

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.825, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-043670 · doc4.xml · nonDerivative · entry 3

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2 MG Limited

Disclosed balance after: 1,375,942

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.825, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-043670 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2-TPO Investments, LLC

Disclosed balance after: 343,385

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-043670 · doc4.xml · nonDerivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2 MG Limited

Disclosed balance after: 1,379,185

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.95, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-042033 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2-TPO Investments, LLC

Disclosed balance after: 344,642

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.805, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F4 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-042033 · doc4.xml · nonDerivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2 MG Limited

Disclosed balance after: 1,386,309

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.805, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 6

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2-TPO Investments, LLC

Disclosed balance after: 344,972

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $25.05, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 5

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2 MG Limited

Disclosed balance after: 1,388,179

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $25.05, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 4

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2-TPO Investments, LLC

Disclosed balance after: 346,137

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.85, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F3 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 3

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2 MG Limited

Disclosed balance after: 1,394,783

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.75 to $24.85, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

F2 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-041423 · doc4.xml · nonDerivative · entry 1

Atillasoy Ercem · CIK 0001818802 · See Remarks

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,986

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.51. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 2

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2-TPO Investments, LLC

Disclosed balance after: 346,996

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F3 · ownership.nature: Shares held by F2-TPO. Globeways Holdings II Limited is the appointed manager of F2-TPO and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2-TPO. The Reporting Person is the founding director of Globeways Holdings II Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings II Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-041467 · doc4.xml · nonDerivative · entry 1

Jovan-Embiricos Morana · CIK 0001575745 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · By F2 MG Limited

Disclosed balance after: 1,399,647

F1 · kind: These sales were effected by F2 MG Limited ("F2 MG") and F2-TPO Investments, LLC ("F2-TPO") pursuant to Rule 10b5-1 trading plans adopted on September 21, 2021.

F2 · ownership.nature: Shares held by F2 MG. Globeways Holdings Limited is the appointed manager of F2 MG and has sole power to vote upon the acquisition, holding and disposal of all shares held by F2 MG. The Reporting Person is the founding director of Globeways Holdings Limited. Morana Jovan-Embiricos has the sole power to vote upon the acquisition, holding and disposal of all shares and warrants held by Globeways Holdings Limited. The Reporting Person disclaims beneficial ownership of these securities except to the extent of her pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-039356 · doc4.xml · nonDerivative · entry 4

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 453,529

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.795 to $26.38. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-039356 · doc4.xml · nonDerivative · entry 3

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 453,862

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.78 to $25.75. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-039356 · doc4.xml · nonDerivative · entry 2

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 456,829

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $23.78 to $24.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-039356 · doc4.xml · nonDerivative · entry 1

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 461,540

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $22.78 to $23.77. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-038676 · doc4.xml · nonDerivative · entry 3

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 418,595

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.22. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-038676 · doc4.xml · nonDerivative · entry 2

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 422,008

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.46. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-038676 · doc4.xml · nonDerivative · entry 1

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 434,179

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.10. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-038191 · doc4.xml · nonDerivative · entry 1

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 472,218

F1 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020.

F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.23. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-036577 · doc4.xml · nonDerivative · entry 4

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 475,968

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 7

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 435,179

F3 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 8, 2020.

F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.16. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-036577 · doc4.xml · nonDerivative · entry 3

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 478,918

F2 · kind: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on December 14, 2020.

F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $24.00 to $24.08. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

SEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 6

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,095

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 5

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 441,608

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-21-036577 · doc4.xml · nonDerivative · entry 2

Melian Agustin · CIK 0001818064 · Chief Medical Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 479,718

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-21-036636 · doc4.xml · nonDerivative · entry 4

VAN BEEK JEROEN B · CIK 0001743662 · Chief Commercial Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 456,813

F1 · kind: Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock, and does not represent a discretionary trade by the reporting person.

SEC source: 0000899243-21-020870 · doc4.xml · derivative · entry 1

GADICKE ANSBERT · CIK 0001134655 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2031-05-24

F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-21-020866 · doc4.xml · derivative · entry 3

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2031-05-24

F3 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders.

SEC source: 0000899243-21-020866 · doc4.xml · nonDerivative · entry 1

Brenner Malcolm · CIK 0001818068 · Director

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 0

F1 · shares: Shares held by Salt Free LP. On May 25, 2021, Salt Free LP distributed to its limited partners, pro rata and without consideration, 818,663 shares of the Issuer's common stock.The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

F1 · ownership.nature: Shares held by Salt Free LP. On May 25, 2021, Salt Free LP distributed to its limited partners, pro rata and without consideration, 818,663 shares of the Issuer's common stock.The Reporting Person has a controlling interest in Salt Free LP and may be deemed to beneficially own these securities. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

SEC source: 0000899243-21-020869 · doc4.xml · derivative · entry 1

Hallal David · CIK 0001457477 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 22,500

Underlying: Common Stock · 22,500 shares

Expires 2031-05-24

F1 · derivative.exercise_date: This option shall vest and become exercisable upon the earlier to occur of (i) May 25, 2022 and (ii) the next annual meeting of the Issuer's stockholders.